Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025.
An ETF portfolio manager highlights how his fund is beating the broader market and what advice he has for investors in 2025 in an exclusive Benzinga interview.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the health insurance providers industry, including CVS Health (NYSE:CVS) and its peers.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the health insurance providers industry, including Cencora (NYSE:COR) and its peers.
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital,
and those that can maintain this trifecta year in and year out often become the legends of the investing world.
Let’s dig into the relative performance of Cigna (NYSE:CI) and its peers as we unravel the now-completed Q4 health insurance providers earnings season.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at UnitedHealth (NYSE:UNH) and its peers.
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the health insurance providers stocks, including Progyny (NASDAQ:PGNY) and its peers.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 1.7%. This performance is a noticeable divergence from the S&P 500’s 8.9% return.
Walgreens Boots Alliance further reduced stake in Cencora. Walgreens reports early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares.
Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance’s sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended.
Healthcare distributor Cencora (NYSE:COR) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 12.8% year on year to $81.49 billion. Its non-GAAP profit of $3.73 per share was 6% above analysts’ consensus estimates.
